S&P 500   4,563.11 (-0.69%)
DOW   36,184.91 (-0.17%)
QQQ   385.05 (-1.25%)
AAPL   188.98 (-1.18%)
MSFT   368.12 (-1.71%)
META   318.06 (-2.08%)
GOOGL   128.91 (-2.24%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.08 (-1.23%)
AMD   118.42 (-2.45%)
T   16.55 (-1.25%)
F   10.67 (+0.85%)
MU   74.09 (-2.42%)
CGC   0.73 (+17.98%)
GE   121.66 (-0.69%)
DIS   92.03 (-0.59%)
AMC   7.30 (+6.41%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.31 (-0.66%)
S&P 500   4,563.11 (-0.69%)
DOW   36,184.91 (-0.17%)
QQQ   385.05 (-1.25%)
AAPL   188.98 (-1.18%)
MSFT   368.12 (-1.71%)
META   318.06 (-2.08%)
GOOGL   128.91 (-2.24%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.08 (-1.23%)
AMD   118.42 (-2.45%)
T   16.55 (-1.25%)
F   10.67 (+0.85%)
MU   74.09 (-2.42%)
CGC   0.73 (+17.98%)
GE   121.66 (-0.69%)
DIS   92.03 (-0.59%)
AMC   7.30 (+6.41%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.31 (-0.66%)
S&P 500   4,563.11 (-0.69%)
DOW   36,184.91 (-0.17%)
QQQ   385.05 (-1.25%)
AAPL   188.98 (-1.18%)
MSFT   368.12 (-1.71%)
META   318.06 (-2.08%)
GOOGL   128.91 (-2.24%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.08 (-1.23%)
AMD   118.42 (-2.45%)
T   16.55 (-1.25%)
F   10.67 (+0.85%)
MU   74.09 (-2.42%)
CGC   0.73 (+17.98%)
GE   121.66 (-0.69%)
DIS   92.03 (-0.59%)
AMC   7.30 (+6.41%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.31 (-0.66%)
S&P 500   4,563.11 (-0.69%)
DOW   36,184.91 (-0.17%)
QQQ   385.05 (-1.25%)
AAPL   188.98 (-1.18%)
MSFT   368.12 (-1.71%)
META   318.06 (-2.08%)
GOOGL   128.91 (-2.24%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.87 (-3.16%)
NIO   7.32 (+2.38%)
BABA   73.08 (-1.23%)
AMD   118.42 (-2.45%)
T   16.55 (-1.25%)
F   10.67 (+0.85%)
MU   74.09 (-2.42%)
CGC   0.73 (+17.98%)
GE   121.66 (-0.69%)
DIS   92.03 (-0.59%)
AMC   7.30 (+6.41%)
PFE   29.35 (+1.52%)
PYPL   59.97 (+0.54%)
XOM   102.31 (-0.66%)

Clearside Biomedical Stock Price, News & Analysis (NASDAQ:CLSD)

$1.10
+0.07 (+6.80%)
(As of 02:33 PM ET)
Compare
Today's Range
$1.06
$1.13
50-Day Range
$0.68
$1.14
52-Week Range
$0.65
$1.85
Volume
149,375 shs
Average Volume
154,325 shs
Market Capitalization
$68.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Clearside Biomedical MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
358.7% Upside
$5.00 Price Target
Short Interest
Healthy
0.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Clearside Biomedical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$65,245 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.56) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

554th out of 951 stocks

Pharmaceutical Preparations Industry

264th out of 439 stocks


CLSD stock logo

About Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Stock Price History

CLSD Stock News Headlines

Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
Clearside Biomedical: Q3 Earnings Insights
Is This The Most Overlooked Gold Investment Strategy of 2024?
There is little debate on the potential of gold in the next year and decade. The real issue becomes - what's the best gold investment strategy today? Some investors are opting for a unique "royalty" alternative that outshines other options like holding gold bullion or investing in volatile mining stocks.
Clearside Biomedical Inc CLSD
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+358.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-32,950,000.00
Net Margins
-1,687.74%
Pretax Margin
-1,687.74%

Debt

Sales & Book Value

Annual Sales
$1.33 million
Book Value
$0.18 per share

Miscellaneous

Free Float
56,293,000
Market Cap
$68.03 million
Optionable
Optionable
Beta
2.30
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. George M. Lasezkay J.D. (Age 71)
    Pharm.D., Pharma.D., President, CEO & Director
    Comp: $816.4k
  • Mr. Charles A. DeignanMr. Charles A. Deignan (Age 59)
    Chief Financial Officer
    Comp: $536.95k
  • Dr. Thomas A. Ciulla M.B.A. (Age 59)
    M.D., Chief Medical Advisor-Retina
    Comp: $597.21k
  • Ms. Jenny R. Kobin (Age 56)
    Head of Investor Relations
  • Mr. Rick McElheny
    Vice President of Corporate Development
  • Mr. Rafael V. Andino (Age 58)
    Senior Vice President of Engineering & Manufacturing
  • Ms. Susan L. Coultas Ph.D.
    Chief Clinical Officer
  • Mr. Leslie B. Zacks (Age 54)
    Secretary














CLSD Stock Analysis - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price target for 2024?

4 brokerages have issued 1-year price objectives for Clearside Biomedical's stock. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2023?

Clearside Biomedical's stock was trading at $1.12 on January 1st, 2023. Since then, CLSD stock has decreased by 2.7% and is now trading at $1.09.
View the best growth stocks for 2023 here
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.22 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 533.87% and a negative net margin of 1,687.74%. During the same quarter in the prior year, the business earned ($0.13) EPS.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Carmignac Gestion (3.42%), Simplex Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Richard T Burke and Thomas Ciulla.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLSD) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -